News | Stents Bioresorbable
The global market value for bioabsorbable scaffolds (BAS) will expand rapidly from $143.7 million in 2014 to just under $2.1 billion by 2021, said research and consulting firm GlobalData. The surge will be driven primarily by new product approvals and a paradigm shift in the clinical treatment of vascular diseases towards minimally-invasive procedures.
August 05, 2015
HeartWare expanded the Class I recall of its ventricular assist device in mid-June due to concerns over damaged or failing device components. The three mid-June recalls are part of a series of five alerts related to the HeartWare VAD dating back to April.
August 05, 2015
August 5, 2015 — Boehringer Ingelheim announced the first U.S. patients have been enrolled in two of the company's ...
August 05, 2015Sponsored Content
Feature
SPONSORED CONTENT — Studycast is a comprehensive imaging workflow system that allows healthcare professionals to work ...
June 17, 2025
News | Heart Valve Technology
Abbott announced Monday that it has entered into an agreement to purchase Tendyne Holdings Inc., a private medical device company focused on developing minimally invasive mitral valve replacement therapies. Under the terms of the agreement, Abbott will acquire the equity of Tendyne that it does not already own for $225 million upfront, resulting in a total transaction value of $250 million, plus potential future payments tied to regulatory milestones.
August 05, 2015
News | Cardiovascular Ultrasound
Over the past several years, advanced heart failure patients who have not responded to medical therapy have been given new hope, and are surviving longer with implanted left ventricular assist devices (LVADs). Although echocardiography is recommended for each phase of care for patients with LVADs, there has been limited published data and no formal guidance for the use of echocardiography in this growing patient population. In an effort to fill this gap, a new document, Echocardiography in the Management of Patients with Left Ventricular Assist Devices: Recommendations from the American Society of Echocardiography, will appear in the August 2015 issue of the Journal of the American Society of Echocardiography (JASE).
August 04, 2015
Triple therapy is no better than dual antiplatelet therapy in preventing major adverse cardiac events in older patients with atrial fibrillation who had a heart attack treated with angioplasty, according to a new study. The study, published in the Journal of the American College of Cardiology, also found that triple therapy resulted in more complications.
August 04, 2015Sponsored Content
Feature | Information Technology
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
March 21, 2024
News | Cardiovascular Business
Jeff Zagoudis, associate editor of the Scranton Gillette Communications’ Healthcare Group publications Imaging ...
August 04, 2015
News | Cardiac Imaging
Specific cardiovascular risk factors are associated with smaller regional brain volumes that may be early indicators of Alzheimer’s disease and dementia, according to a study published online in the journal Radiology. Those factors include alcohol consumption, smoking, obesity and diabetes.
August 04, 2015
Biotronik announced CE approval of 3 Tesla (T) magnetic resonance imaging (MRI) scanning with exclusion zone for its two latest generations of pacemakers. The company now offers both implantable cardioverter-defibrillators (ICDs) and pacemakers approved for 3T scans.
August 03, 2015Sponsored Content
Feature | Cardiac Imaging
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
March 05, 2024
News | Heart Failure
Sunshine Heart announced plans to commence a first-in-human study using its novel C-Pulse transcutaneous energy transmission (TET) system and a new, smaller implantable pump in quarter three 2016.
August 03, 2015
Technology | Intravascular Imaging
Pie Medical Imaging announced the release of CAAS IntraVascular 2.0, the dedicated software for analysis of intravascular ultrasound (IVUS), near-infrared spectroscopy (NIRS)-IVUS and optical coherence tomography (OCT) datasets. This new release contains an optimized OCT analysis and the in-depth analysis of NIRS-IVUS datasets. Data can be imported easily from the console or picture archiving and communication system (PACS) into the study list, which provides a clear overview of your data. CAAS IntraVascular has U.S. Food and Drug Administration (FDA) 510(k) clearance for both IVUS and OCT.
August 03, 2015
Feature | Stents
According to a new report on the Europe market for interventional cardiology by iData Research, drug-eluting stents accounted for a significant portion of the European markets for interventional cardiology devices in 2014. The advent of drug-eluting stents has driven the interventional cardiology market beyond expectations, as these devices have managed to increase the size of the market by virtue of their relatively high average selling price (ASP). New developments in drug-eluting stents such as biodegradable materials are expected to keep the market competitive despite safety concerns regarding late stent thrombosis.
July 31, 2015Sponsored Content
Blog
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
December 11, 2023
News | Cardiovascular Ultrasound
The American Society of Echocardiography (ASE) released a new document describing various imaging strategies for diagnosing a “hole in the heart,” one of the most common types of congenital heart defects. The document, Guidelines for the Echocardiographic Assessment of Atrial Septal Defect and Patent Foramen Ovale: From the American Society of Echocardiography and Society for Cardiac Angiography and Interventions, describes the various defects, the modalities used to evaluate them, and clearly lays out strategies for optimal imaging.
July 31, 2015
News | Ultrasound Imaging
After a tornado decimated the hospital only four years ago, Mercy Hospital Joplin in Joplin, Missouri, reopened its doors in March with a new, 900,000-square-foot facility with state-of-the-art equipment. Part of the acquisition by Mercy Hospital Joplin, formerly St. John’s Regional Medical Center, included eight Aplio 300 Platinum ultrasound systems from Toshiba America Medical Systems Inc.
July 30, 2015
Navidea Biopharmaceuticals Inc. announced plans to move forward with a joint study of the ability of Tc99m-tilmanocept, a Manocept platform product, to localize in high-risk atherosclerotic plaques. The study — funded through a $321,000 Phase 1 Small Business Innovation Research (SBIR) grant from the National Heart, Lung and Blood Institute (NHLBI), National Institute of Health (NIH) — will be conducted with Massachusetts General Hospital (MGH) and Harvard Medical School.
July 30, 2015